Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy. On January 20, RBC Capital increased Ascendis Pharma A/S (NASDAQ:ASND)’s price target to $250 from $245 while maintaining an Outperform rating on the company. The firm’s improved projection comes after Ascendis Pharma A/S (NASDAQ:ASND) announced major goals for 2026, with the company estimating maintaining launch momentum for Yorvipath with no drop in patient intakes. Ascendis Pharma A/S (NASDAQ:ASND) stated that t ...

Ascendis Pharma A/S (NASDAQ:ASND) is one of the 11 Best Stocks to Buy for Investment. On January 27, BofA reiterated a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND). Tazeen Ahmad at BofA retained the rating on ASND and maintained the price target at $246. BofA Reiterates Buy Rating on Ascendis Pharma, While Wells Fargo Analyst Upgrades PT on ASND adriaticfoto/Shutterstock.com In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pha ...

Ascendis Pharma A/S (ASND) shares rallied 3% in the last trading session to close at $215.05. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.1% loss over the past four weeks.The sudden jump in the stock price is likely fueled by the commercial performance of Ascendis Pharma’s two marketed drugs, Skytrofa and Yorvipath, approved for growth hormone deficiency and hypoparathyroidism, respectively. Last week, ...

Core Viewpoint - Ascendis Pharma is participating in the 44th Annual JPMorgan Healthcare Conference, highlighting its focus on commercialization and development of its products, particularly SKYTROFA and YORVIPATH [1][3]. Group 1: Company Overview - The CEO of Ascendis Pharma, Jan Mikkelsen, is set to present at the conference, indicating the company's commitment to engaging with investors and stakeholders [1]. - Scott Smith, the CFO, has initiated the conference call, emphasizing the importance of forward-looking statements for the company's strategic direction [2][3]. Group 2: Forward-Looking Statements - The conference will include forward-looking statements related to commercialization, development expectations for SKYTROFA and YORVIPATH, and revenue growth projections [3]. - Statements will also cover pipeline candidates, their associated costs, and expectations regarding clinical trials and regulatory filings [3].

Ascendis Pharma FY Conference Summary Company Overview - **Company**: Ascendis Pharma (NasdaqGS:ASND) - **Industry**: Biotechnology - **Conference Date**: January 12, 2026 Key Points Financial Performance - Q4 product revenue reached approximately **EUR 240 million**, with total annual revenue of about **EUR 683 million** [6][35] - Revenue growth is primarily driven by two products: **Yorvipath** and **Skytrofa** [6][35] - Ascendis Pharma aims for revenue exceeding **EUR 5 billion** by 2030, with a significant portion expected from the U.S. market [8][9] Product Pipeline and Development - Ascendis Pharma is focused on the commercialization and development of **Skytrofa** and **Yorvipath**, with ongoing clinical trials and regulatory filings [2][6] - The company is expanding its pipeline in rare diseases, particularly in endocrinology, with plans for **two to three new product opportunities** [9][10] - **TransCon CNP** is expected to receive regulatory approval in February 2026, with a strong emphasis on its unique benefits for patients [23][36] Market Strategy - Ascendis Pharma is actively working on increasing provider education and patient activation, particularly in the U.S. where penetration is currently low [40][41] - The company plans to expand its commercial presence in Europe, targeting at least **10 additional countries** for product launches in 2026 [13][41] - Ascendis Pharma is also focusing on optimizing patient access and support, which is crucial for rare disease treatments [41] Competitive Landscape - The company believes it has a unique position in the market due to its **TransCon technology**, which allows for sustained drug exposure and differentiation from competitors [10][48] - Ascendis Pharma anticipates that **Yorvipath** could achieve peak sales of **$5-$8 billion** globally, highlighting its strong market potential [48] Research and Development - The company has a robust R&D pipeline, with aspirations for **eight or more new chemical entities** and **25 indications** by 2035 [11][36] - Ascendis Pharma is committed to maintaining high safety and efficacy standards in its products, particularly in pediatric indications [27][33] Future Outlook - Ascendis Pharma is optimistic about continued growth in 2026, driven by the expansion of its product offerings and market penetration strategies [39][44] - The company is focused on long-term sustainability and profitability, with plans for share buybacks and maintaining a strong cash balance of **€615 million** [36][38] Additional Insights - Ascendis Pharma's approach to product development emphasizes the importance of patient safety and the potential for significant clinical benefits, particularly in growth disorders [32][33] - The company is leveraging partnerships, such as with **Novo Nordisk** for obesity treatments, to diversify its product offerings and enhance market reach [10][34] This summary encapsulates the key insights from the Ascendis Pharma FY Conference, highlighting the company's financial performance, product pipeline, market strategies, and future outlook in the biotechnology industry.

Ascendis Pharma A/S J.P. Morgan Healthcare Conference San Francisco January 2026 This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which w ...

Core Insights - Ascendis Pharma is rapidly transforming into a leading global biopharma company, driven by its TransCon technology platform, strong R&D capabilities, and expanding commercial infrastructure [2][3] Business and Strategic Roadmap - The company plans to present its business and strategic roadmap, including key corporate milestones for 2026, at the J.P. Morgan Healthcare Conference on January 12, 2026 [1][6] - Ascendis aims for further global penetration and commercial expansion, with a third potential TransCon product approval expected to have blockbuster potential [2] Key Updates and Milestones - TransCon PTH (YORVIPATH) is expected to generate approximately €187 million in Q4 2025 and €477 million for the full year 2025, with over 5,300 unique U.S. patient enrollments [3] - TransCon hGH (SKYTROFA) is projected to have revenues of around €53 million in Q4 2025 and €206 million for the full year 2025, with FDA approval for adult growth hormone deficiency received in July 2025 [3] - TransCon CNP has a PDUFA goal date of February 28, 2026, for pediatric achondroplasia, with a marketing authorization application submitted to the EMA [3] - The combination therapy of TransCon CNP and TransCon hGH showed significant improvements in growth velocity in the Phase 2 COACH Trial [3] Financial Update - Ascendis reported an estimated total product revenue of approximately €683 million for 2025, with a gross margin expected to be around 87% [4] - The company has authorized a $120 million share repurchase program, with a preliminary cash balance of approximately €616 million as of December 31, 2025 [4] Strategic Collaborations - Ascendis has ongoing collaborations with Novo Nordisk for therapies in obesity and metabolic diseases, and with Eyconis, VISEN Pharmaceuticals, and Teijin Limited for various TransCon products [5]

Group 1 - The call is led by Scott Smith, CFO of Ascendis Pharma, along with other key executives including Jan Moller Mikkelsen and Aimee Shu [2] - The presentation includes forward-looking statements related to the development of TransCon CNP and TransCon Growth Hormone combination treatment, as well as pipeline candidates [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Ascendis Pharma (NasdaqGS:ASND) Update / Briefing January 08, 2026 04:30 PM ET Company ParticipantsJoseph Schwartz - Senior Managing DirectorTazeen Ahmad - Managing Director in US Equity ResearchScott Smith - EVP and CFODerek Archila - Managing DirectorYun Zhong - Senior Vice President of Equity ResearchLi Watsek - DirectorGavin Clark-Gartner - Managing Director of Biotechnology Equity ResearchJan Møller Mikkelsen - President and CEOAimee Shu - EVP and Chief Medical OfficerMaxwell Skor - Vice President of B ...